{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:29:27Z","timestamp":1793521767221,"version":"4.5.0"},"reference-count":175,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Universit\u00e9 Paris Cit\u00e9 and AMRO Foundation"},{"name":"European Union\u2019s Horizon 2020 research and innovation program","award":["825575"],"award-info":[{"award-number":["825575"]}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["JCM"],"abstract":"<jats:p>Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a vascular disorder with a global prevalence ranging from 1:5000 to 1:8000. It most commonly manifests through nosebleeds, which can be frequent and severe, exposing patients to major iron losses, anemia, and considerable physical and emotional distress. To date, no drug has received the FDA or EMA approval for preventing or treating HHT associated epistaxis, limiting access to therapies and intensifying the burden on patients and clinicians. Based on peer-reviewed evidence, the Second International HHT Guidelines provided a stepwise approach to help physicians manage HHT-related epistaxis highlighting the role of anti-fibrinolytic and systemic antiangiogenic drugs. However, experience from clinical practice and trials indicates marked variability in patient responses, and none of the recommended approaches has demonstrated sufficient placebo-controlled efficacy to gain regulatory approval. Striking insights in HHT physiopathology shed light on complex dysregulated signaling pathways with a triggering role not only by angiogenesis as widely recognized, but also by inflammation, injury and other stimuli, pointing to novel therapeutic targets. This review outlines current recommendations for preventing and managing nosebleeds in HHT patients, highlights the latest insights into the development of telangiectasic lesions, and discusses potential therapeutic treatments currently under clinical investigation.<\/jats:p>","DOI":"10.3390\/jcm14217724","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:28:43Z","timestamp":1761888523000},"page":"7724","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia"],"prefix":"10.3390","volume":"14","author":[{"given":"Anthony","family":"Ficany","sequence":"first","affiliation":[{"name":"INSERM, U1144 Optimisation Th\u00e9rapeutique en Neuropharmacologie (OPTeN), Faculty of Pharmacy, Universit\u00e9 Paris-Cit\u00e9, 75006 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Del Alamo","sequence":"additional","affiliation":[{"name":"ECRIN\u2013European Clinical Research Infrastructure Network, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1563-6162","authenticated-orcid":false,"given":"Carmelo","family":"Bernabeu","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Centro de Investigaciones Biol\u00f3gicas \u201cMargarita Salas\u201d, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9007-5775","authenticated-orcid":false,"given":"Claire L.","family":"Shovlin","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London W12 0NN, UK"},{"name":"Specialist Medicine, Imperial College Healthcare NHS Trust, London W12 0HS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0570-6104","authenticated-orcid":false,"given":"Elisa","family":"Rossi","sequence":"additional","affiliation":[{"name":"INSERM, U1144 Optimisation Th\u00e9rapeutique en Neuropharmacologie (OPTeN), Faculty of Pharmacy, Universit\u00e9 Paris-Cit\u00e9, 75006 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-024-00585-z","article-title":"Hereditary haemorrhagic telangiectasia","volume":"11","author":"Hermann","year":"2025","journal-title":"Nat. Rev. Dis. Primer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","article-title":"Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)","volume":"91","author":"Shovlin","year":"2000","journal-title":"Am. J. Med. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104370","DOI":"10.1016\/j.ejmg.2021.104370","article-title":"The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care","volume":"65","author":"Shovlin","year":"2022","journal-title":"Eur. J. Med. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/thoraxjnl-2021-218332","article-title":"Pulmonary arteriovenous malformations may be the only clinical criterion present in genetically confirmed hereditary haemorrhagic telangiectasia","volume":"77","author":"Anderson","year":"2022","journal-title":"Thorax"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"113665","DOI":"10.1016\/j.jpeds.2023.113665","article-title":"Longitudinal Assessment of Cura\u00e7ao Criteria in Children with Hereditary Hemorrhagic Telangiectasia","volume":"263","author":"Pollak","year":"2023","journal-title":"J. Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/03014469200002112","article-title":"An abnormal concentration of cases of Rendu-Osler disease in the Valserine valley of the French Jura: A genealogical and demographic study","volume":"19","author":"Bideau","year":"1992","journal-title":"Ann. Hum. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/ajmg.a.10002","article-title":"The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: A family screening","volume":"116A","author":"Westermann","year":"2003","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/thoraxjnl-2013-203720","article-title":"The UK prevalence of hereditary haemorrhagic telangiectasia and its association with sex, socioeconomic status and region of residence: A population-based study","volume":"69","author":"Donaldson","year":"2014","journal-title":"Thorax"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e005061","DOI":"10.1161\/CIRCGEN.124.005061","article-title":"Hereditary Hemorrhagic Telangiectasia Prevalence Estimates Calculated From GnomAD Allele Frequencies of Predicted Pathogenic Variants in ENG and ACVRL1","volume":"18","author":"Anzell","year":"2025","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1182\/blood.2023021777","article-title":"Mutations causing premature termination codons discriminate and generate cellular and clinical variability in HHT","volume":"143","author":"Patel","year":"2024","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood.2019004560","article-title":"Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia","volume":"136","author":"Shovlin","year":"2020","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/ajmg.a.62584","article-title":"Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations","volume":"188","author":"Balachandar","year":"2022","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/jmg-2023-109195","article-title":"Updates on diagnostic criteria for hereditary haemorrhagic telangiectasia in the light of whole genome sequencing of \u2018gene-negative\u2019 individuals recruited to the 100 000 Genomes Project","volume":"61","author":"Shovlin","year":"2024","journal-title":"J. Med. Genet."},{"key":"ref_15","first-page":"2155","article-title":"A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7","volume":"140","author":"McDonald","year":"2006","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/thx.2007.087452","article-title":"Primary determinants of ischaemic stroke\/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia","volume":"63","author":"Shovlin","year":"2008","journal-title":"Thorax"},{"key":"ref_17","unstructured":"(2025, May 14). Vascular Anomalies (VASCA-WG) | VASCERN. Available online: https:\/\/vascern.eu\/group\/vascular-anomalies\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/bjh.19167","article-title":"MEK 1 inhibition and bleeding in hereditary haemorrhagic telangiectasia","volume":"204","author":"Shovlin","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2018.193003","article-title":"Hereditary hemorrhagic telangiectasia: Diagnosis and management from the hematologist\u2019s perspective","volume":"103","author":"Kritharis","year":"2018","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1007\/s10620-017-4719-3","article-title":"Gastrointestinal Manifestations of Hereditary Hemorrhagic Telangiectasia (HHT): A Systematic Review of the Literature","volume":"62","author":"Jackson","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1288\/00005537-199109000-00008","article-title":"The natural history of epistaxis in hereditary hemorrhagic telangiectasia","volume":"101","author":"AAssar","year":"1991","journal-title":"Laryngoscope"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An epistaxis severity score for hereditary hemorrhagic telangiectasia","volume":"120","author":"Hoag","year":"2010","journal-title":"Laryngoscope"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/alr.21374","article-title":"The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia","volume":"4","author":"Merlo","year":"2014","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMc1213554","article-title":"Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia","volume":"368","author":"Devlin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/thoraxjnl-2011-201076","article-title":"Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli\/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia","volume":"67","author":"Livesey","year":"2012","journal-title":"Thorax"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1007\/s10620-011-1585-2","article-title":"Natural History and Outcome of Hepatic Vascular Malformations in a Large Cohort of Patients with Hereditary Hemorrhagic Teleangiectasia","volume":"56","author":"Buscarini","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/thoraxjnl-2017-210764","article-title":"British Thoracic Society British Thoracic Society Clinical Statement on Pulmonary Arteriovenous Malformations","volume":"72","author":"Shovlin","year":"2017","journal-title":"Thorax"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e70037","DOI":"10.1002\/pul2.70037","article-title":"Elective Thoracic Surgical Resections for Pulmonary Arteriovenous Malformations\u2014A 16 Year Single-Center Experience","volume":"15","author":"Anderson","year":"2025","journal-title":"Pulm. Circ."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Shovlin, C.L., Chamali, B., Santhirapala, V., Livesey, J.A., Angus, G., Manning, R., Laffan, M.A., Meek, J., Tighe, H.C., and Jackson, J.E. (2014). Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: Associations with iron deficiency and platelets. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0088812"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1212\/WNL.0000000000013169","article-title":"Ischemic Stroke and Pulmonary Arteriovenous Malformations: A Review","volume":"98","author":"Topiwala","year":"2022","journal-title":"Neurology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"00035","DOI":"10.1183\/23120541.00035-2016","article-title":"Embolisation of PAVMs reported to improve nosebleeds by a subgroup of patients with hereditary haemorrhagic telangiectasia","volume":"2","author":"Shovlin","year":"2016","journal-title":"ERJ Open Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1002\/lary.25959","article-title":"Can Iron Treatments Aggravate Epistaxis in Some Patients With Hereditary Hemorrhagic Telangiectasia?","volume":"126","author":"Shovlin","year":"2016","journal-title":"Laryngoscope"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/lary.25669","article-title":"The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia","volume":"126","author":"Yin","year":"2016","journal-title":"Laryngoscope"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/ajh.70011","article-title":"Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report","volume":"100","author":"Kasthuri","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jamaoto.2025.0017","article-title":"A Framework for Clinical Trials in Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis-Navigating the PATH","volume":"151","author":"Peterson","year":"2025","journal-title":"JAMA Otolaryngol.-Head Neck Surg."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Finnamore, H., Le Couteur, J., Hickson, M., Busbridge, M., Whelan, K., and Shovlin, C.L. (2013). Hemorrhage-Adjusted Iron Requirements, Hematinics and Hepcidin Define Hereditary Hemorrhagic Telangiectasia as a Model of Hemorrhagic Iron Deficiency. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076516"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11882-023-01116-8","article-title":"Treatments of Epistaxis in Hereditary Hemorrhagic Telangiectasia: Systematic Review and Network Meta-Analysis","volume":"23","author":"Chitsuthipakorn","year":"2023","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/joim.13714","article-title":"Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial","volume":"294","author":"Lavigne","year":"2023","journal-title":"J. Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.anorl.2024.10.006","article-title":"Treatment of Epistaxis in Osler-Weber-Rendu Disease by Bevacizumab Nasal Spray. The EROSB Study: Determining the Effective Dose","volume":"142","author":"Vincent","year":"2025","journal-title":"Eur. Ann. Otorhinolaryngol. Head Neck Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.2016.11387","article-title":"Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial","volume":"316","author":"Ambrun","year":"2016","journal-title":"JAMA"},{"key":"ref_41","first-page":"794","article-title":"ELLIPSE Study: A Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia","volume":"6","author":"Ambrun","year":"2014","journal-title":"mAbs"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/hed.23655","article-title":"Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: A double-blind, randomized, placebo-controlled trial","volume":"37","author":"Riss","year":"2015","journal-title":"Head Neck"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.2016.11724","article-title":"Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial","volume":"316","author":"Whitehead","year":"2016","journal-title":"JAMA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s13023-022-02539-8","article-title":"Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia","volume":"17","author":"Thompson","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/jth.15662","article-title":"North American Study for the Treatment of Recurrent Epistaxis with Doxycycline: The NOSTRIL trial","volume":"20","author":"McWilliams","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40463-019-0379-y","article-title":"Prospective Pilot Study of Floseal\u00ae for the Treatment of Anterior Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia (HHT)","volume":"48","author":"Lee","year":"2019","journal-title":"J. Otolaryngol. Head Neck Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10456-020-09758-2","article-title":"Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: A proof of concept study","volume":"24","author":"Kroon","year":"2021","journal-title":"Angiogenesis"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10456-024-09962-4","article-title":"Effect of oral nintedanib vs. placebo on epistaxis in hereditary hemorrhagic telangiectasia: The EPICURE multicenter randomized double-blind trial","volume":"28","author":"Hermann","year":"2025","journal-title":"Angiogenesis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10456-018-9646-1","article-title":"Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia","volume":"22","author":"Faughnan","year":"2019","journal-title":"Angiogenesis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2312749","article-title":"Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia","volume":"391","author":"Kasthuri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/alr.21484","article-title":"Prospective randomized trial of sclerotherapy vs. standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia","volume":"5","author":"Boyer","year":"2015","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Dupuis-Girod, S., Fargeton, A.-E., Grobost, V., Rivi\u00e8re, S., Beaudoin, M., Decullier, E., Bernard, L., Br\u00e9ant, V., Colombet, B., and Philouze, P. (2020). Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051262"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/lary.20065","article-title":"Antiestrogen therapy for hereditary hemorrhagic telangiectasia: A double-blind placebo-controlled clinical trial","volume":"119","author":"Yaniv","year":"2009","journal-title":"Laryngoscope"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4193\/Rhino09.201","article-title":"Anti-estrogen therapy for hereditary hemorrhagic telangiectasia\u2014A long-term clinical trial","volume":"49","author":"Yaniv","year":"2011","journal-title":"Rhinology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2352-3026(15)00195-7","article-title":"Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia: Results of a prospective phase II clinical trial","volume":"2","author":"Invernizzi","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Dupuis-Girod, S., Pitiot, V., Bergerot, C., Fargeton, A.-E., Beaudoin, M., Decullier, E., Br\u00e9ant, V., Colombet, B., Philouze, P., and Faure, F. (2019). Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-48502-9"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jamaoto.2020.3025","article-title":"Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia\u2013Associated Epistaxis: A Randomized Clinical Trial","volume":"146","author":"Peterson","year":"2020","journal-title":"JAMA Otolaryngol.-Head Neck Surg."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.thromres.2014.06.012","article-title":"Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid\u2014A double-blind placebo-controlled cross-over phase IIIB study","volume":"134","author":"Geisthoff","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jth.12654","article-title":"Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: A European cross-over controlled trial in a rare disease","volume":"12","author":"Gaillard","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5603\/AIT.a2015.0011","article-title":"Tranexamic acid: A clinical review","volume":"47","author":"Ng","year":"2015","journal-title":"Anaesthesiol. Intensive Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"bcr2014204138","DOI":"10.1136\/bcr-2014-204138","article-title":"Tranexamic acid-induced ligneous conjunctivitis with renal failure showed reversible hypoplasminogenaemia","volume":"2014","author":"Song","year":"2014","journal-title":"BMJ Case Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e12456","DOI":"10.1002\/emp2.12456","article-title":"Color vision disturbances secondary to oral tranexamic acid","volume":"2","author":"Kiser","year":"2021","journal-title":"J. Am. Coll. Emerg. Physicians Open"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1684\/ejd.2014.2354","article-title":"Generalized fixed drug eruption induced by tranexamic acid","volume":"24","author":"Kaku","year":"2014","journal-title":"Eur. J. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI63375","article-title":"Tranexamic acid concentrations associated with human seizures inhibit glycine receptors","volume":"122","author":"Lecker","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_65","unstructured":"HALT-IT Trial Collaborators (2020). Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): An international randomised, double-blind, placebo-controlled trial. Lancet, 395, 1927\u20131936."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jss.2024.07.042","article-title":"Tranexamic Acid Use in the Surgical Arena: A Narrative Review","volume":"302","author":"Mergoum","year":"2024","journal-title":"J. Surg. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF00554669","article-title":"Pharmacokinetics and bioavailability of tranexamic acid","volume":"20","author":"Pilbrant","year":"1981","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/nep.12762","article-title":"Manifestation of tranexamic acid toxicity in chronic kidney disease and kidney transplant patients: A report of four cases and review of literature","volume":"22","author":"Ma","year":"2017","journal-title":"Nephrology"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Marcos, S., Botella, L.M., Albi\u00f1ana, V., Arbia, A., and de Rosales, A.M. (2021). Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173845"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/lary.23893","article-title":"Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia","volume":"123","author":"Silva","year":"2013","journal-title":"Laryngoscope"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4193\/Rhino11.142","article-title":"Local sclerotherapy with polydocanol (Aethoxysklerol\u00ae) for the treatment of Epistaxis in Rendu-Osler-Weber or Hereditary Hemorrhagic Telangiectasia (HHT): 15 years of experience","volume":"50","author":"Morais","year":"2012","journal-title":"Rhinology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamaoto.2025.2296","article-title":"Consensus on Sclerotherapy for Patients With Hereditary Hemorrhagic Telangiectasia-Related Epistaxis","volume":"151","author":"Farneti","year":"2025","journal-title":"JAMA Otolaryngol.-Head Neck Surg."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kumar, N., Lan\u00e7a Gomes, P., Marino, M.J., Miglani, A., and Lal, D. (2024). Innovations in the management of epistaxis secondary to hereditary hemorrhagic telangiectasia: Our evolution to injection sclerotherapy as the treatment of choice. Front. Allergy, 5.","DOI":"10.3389\/falgy.2024.1456686"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/lary.29701","article-title":"Sclerotherapy Versus Cautery\/Laser Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia","volume":"132","author":"Woodard","year":"2022","journal-title":"Laryngoscope"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"103409","DOI":"10.1016\/j.amjoto.2022.103409","article-title":"Duration of effectiveness of coblation for recurrent epistaxis in hereditary hemorrhagic telangiectasia","volume":"43","author":"Feller","year":"2022","journal-title":"Am. J. Otolaryngol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2500\/ajra.2012.26.3809","article-title":"The Young\u2019s procedure for severe epistaxis from hereditary hemorrhagic telangiectasia","volume":"26","author":"Richer","year":"2012","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4193\/Rhin16.315","article-title":"Nasal closure for severe hereditary haemorrhagic telangiectasia in 100 patients. The Lund modification of the Young\u2019s procedure: A 22-year experience","volume":"55","author":"Lund","year":"2017","journal-title":"Rhinology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","article-title":"Bevacizumab-Induced Hypertension: Clinical Presentation and Molecular Understanding","volume":"182","author":"Li","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding","volume":"93","author":"Iyer","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9440(10)64939-5","article-title":"Hereditary hemorrhagic telangiectasia: A model for blood vessel growth and enlargement","volume":"156","author":"Jacobson","year":"2000","journal-title":"Am. J. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000046618","article-title":"Angiogenesis and hereditary hemorrhagic telangiectasia. Rendu-Osler-Weber disease","volume":"106","author":"Cirulli","year":"2001","journal-title":"Acta Haematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000072411","article-title":"Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia","volume":"110","author":"Cirulli","year":"2003","journal-title":"Acta Haematol."},{"key":"ref_84","first-page":"591","article-title":"Plasma level and tissue expression of angiogenic factors in patients with hereditary hemorrhagic telangiectasia","volume":"15","author":"Sadick","year":"2005","journal-title":"Int. J. Mol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00277-006-0147-8","article-title":"Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab","volume":"85","author":"Flieger","year":"2006","journal-title":"Ann. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/lt.21417","article-title":"Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia","volume":"14","author":"Mitchell","year":"2008","journal-title":"Liver Transplant."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMc0901421","article-title":"Bevacizumab in Hereditary Hemorrhagic Telangiectasia","volume":"360","author":"Bose","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_88","first-page":"948","article-title":"Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output","volume":"307","author":"Ginon","year":"2012","journal-title":"JAMA"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2500\/ar.2014.5.0091","article-title":"Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia","volume":"5","author":"Thompson","year":"2014","journal-title":"Allergy Rhinol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"E313","DOI":"10.1002\/ajh.24367","article-title":"Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding","volume":"91","author":"Epperla","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"E641","DOI":"10.1002\/ajh.24878","article-title":"Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in Hereditary Hemorrhagic Telangiectasia","volume":"92","author":"Chavan","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_92","first-page":"2161","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: The InHIBIT-Bleed study","volume":"106","author":"Kasthuri","year":"2021","journal-title":"Haematologica"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-018-0982-4","article-title":"Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia","volume":"14","author":"Buscarini","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/lary.21415","article-title":"Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis","volume":"121","author":"Karnezis","year":"2011","journal-title":"Laryngoscope"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/alr.22961","article-title":"Randomized, controlled, double-blinded clinical trial of effect of bevacizumab injection in management of epistaxis in hereditary hemorrhagic telangiectasia patients undergoing surgical cauterization","volume":"12","author":"Khanwalkar","year":"2022","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1182\/bloodadvances.2024012589","article-title":"Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia","volume":"8","author":"Wang","year":"2024","journal-title":"Blood Adv."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1017\/S0022215118001536","article-title":"The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: Systematic review","volume":"132","author":"Harrison","year":"2018","journal-title":"J. Laryngol. Otol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nm.2131","article-title":"Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia","volume":"16","author":"Lebrin","year":"2010","journal-title":"Nat. Med."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Jung, Y.J., Tweedie, D., Scerba, M.T., Kim, D.S., Palmas, M.F., Pisanu, A., Carta, A.R., and Greig, N.H. (2021). Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders. Front. Neurosci., 15.","DOI":"10.3389\/fnins.2021.656921"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1016-8478(23)13028-7","article-title":"The effects of thalidomide on the stimulation of NF-kappaB activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line","volume":"17","author":"Kim","year":"2004","journal-title":"Mol. Cells"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/j.jtha.2023.06.007","article-title":"Novel vascular roles of human endoglin in pathophysiology","volume":"21","author":"Rossi","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_102","first-page":"1189","article-title":"TNF alpha down-regulates CD105 expression in vascular endothelial cells: A comparative study with TGF beta 1","volume":"23","author":"Li","year":"2003","journal-title":"Anticancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4193\/Rhino14.289","article-title":"Follow-up of Thalidomide treatment in patients with Hereditary Haemorrhagic Telangiectasia","volume":"53","author":"Hosman","year":"2015","journal-title":"Rhinology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/0194599817700573","article-title":"Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study","volume":"157","author":"Fang","year":"2017","journal-title":"Otolaryngol.-Head Neck Surg."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Ugur, M.C., Baysal, M., and Umit, E.G. (2024). The Role of Thalidomide and Its Analogs in the Treatment of Hereditary Hemorrhagic Telangiectasia: A Systematic Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13185404"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijpharm.2016.07.002","article-title":"Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia","volume":"514","author":"Colombo","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Kopp, K.O., Greer, M.E., Glotfelty, E.J., Hsueh, S.-C., Tweedie, D., Kim, D.S., Reale, M., Vargesson, N., and Greig, N.H. (2023). A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders. Biomolecules, 13.","DOI":"10.3390\/biom13050747"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/BF03401909","article-title":"Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity","volume":"2","author":"Corral","year":"1996","journal-title":"Mol. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","article-title":"Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects","volume":"87","author":"Dredge","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1365-2141.2009.07730.x","article-title":"Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: Potential implications for angiodysplasias?","volume":"146","author":"Bowcock","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1182\/blood-2019-127344","article-title":"Pomalidomide Reduces Bleeding and Alters Expression of Angiogenesis-Related Proteins in Patients with Hereditary Hemorrhagic Telangiectasia","volume":"134","author":"Swaidani","year":"2019","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"LBA-3","DOI":"10.1182\/blood-2023-191983","article-title":"PATH-HHT, a Double-Blind, Randomized, Placebo-Controlled Trial in Hereditary Hemorrhagic Telangiectasia Demonstrates That Pomalidomide Reduces Epistaxis and Improves Quality of Life","volume":"142","author":"Kasthuri","year":"2023","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMc2413110","article-title":"Pomalidomide in Hereditary Hemorrhagic Telangiectasia","volume":"391","author":"Modarresi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCRESAHA.121.318145","article-title":"Genetic Basis and Therapies for Vascular Anomalies","volume":"129","author":"Queisser","year":"2021","journal-title":"Circ. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1161\/ATVBAHA.118.310760","article-title":"ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation","volume":"38","author":"Figueiredo","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"13650","DOI":"10.1038\/ncomms13650","article-title":"PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia","volume":"7","author":"Ola","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Iriarte, A., Figueras, A., Cerd\u00e0, P., Mora, J.M., Jucgl\u00e0, A., Pen\u00edn, R., Vi\u00f1als, F., and Riera-Mestre, A. (2019). PI3K (Phosphatidylinositol 3-Kinase) Activation and Endothelial Cell Proliferation in Patients with Hemorrhagic Hereditary Telangiectasia Type 1. Cells, 8.","DOI":"10.3390\/cells8090971"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors\u2014A review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr. Drug Metab."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/jth.13683","article-title":"Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia","volume":"15","author":"Kim","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/lary.27129","article-title":"Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia","volume":"128","author":"Parambil","year":"2018","journal-title":"Laryngoscope"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10456-021-09807-4","article-title":"Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia","volume":"25","author":"Parambil","year":"2022","journal-title":"Angiogenesis"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"bcr2017219393","DOI":"10.1136\/bcr-2017-219393","article-title":"Nintedanib as a novel treatment option in hereditary haemorrhagic telangiectasia","volume":"2017","author":"Holzmann","year":"2017","journal-title":"BMJ Case Rep."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Al-Samkari, H. (2024, December 13). A Randomized, Placebo-Controlled, Multicenter Proof-of-Concept (POC) Study to Assess the Safety and Efficacy of the Novel Allosteric AKT Inhibitor, VAD044, in Adults with Hereditary Hemorrhagic Telangiectasia (HHT). In ASH. Available online: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper206244.html.","DOI":"10.1182\/blood-2024-206244"},{"key":"ref_124","unstructured":"Vaderis Therapeutics AG (2025, April 24). Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary Hemorrhagic Telangiectasia. Vaderis. Available online: https:\/\/vaderis.com\/fda-fast-track-designation-for-vad044\/."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Beuret, L., Fortier-Beaulieu, S.-P., Rondeau, V., Roy, S., Houde, N., Balabanian, K., Esp\u00e9li, M., and Charron, J. (2021). Mek1 and Mek2 Functional Redundancy in Erythropoiesis. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.639022"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Mohammed, K.A.K., Madeddu, P., and Avolio, E. (2024). MEK inhibitors: A promising targeted therapy for cardiovascular disease. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1404253"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/carcin\/bgq199","article-title":"The TGF-beta co-receptor endoglin modulates the expression and transforming potential of H-Ras","volume":"31","author":"Santibanez","year":"2010","journal-title":"Carcinogenesis"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"21507","DOI":"10.1074\/jbc.M700176200","article-title":"The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells","volume":"282","author":"Lee","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"Hubiche","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.vph.2010.08.002","article-title":"Propranolol suppresses angiogenesis in vitro: Inhibition of proliferation, migration, and differentiation of endothelial cells","volume":"53","author":"Lamy","year":"2010","journal-title":"Vascul. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1160\/TH11-11-0809","article-title":"Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia","volume":"108","author":"Zarrabeitia","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40463-017-0235-x","article-title":"Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia\u2014A preliminary report","volume":"46","author":"Blau","year":"2017","journal-title":"J. Otolaryngol.-Head Neck Surg."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Mei-Zahav, M., Gendler, Y., Bruckheimer, E., Prais, D., Birk, E., Watad, M., Goldschmidt, N., and Soudry, E. (2020). Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103130"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Li, C.-L., Fang, Z.-X., Wu, Z., Hou, Y.-Y., Wu, H.-T., and Liu, J. (2022). Repurposed itraconazole for use in the treatment of malignancies as a promising therapeutic strategy. Biomed. Pharmacother., 154.","DOI":"10.1016\/j.biopha.2022.113616"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1021\/cb600362d","article-title":"Inhibition of angiogenesis by the antifungal drug itraconazole","volume":"2","author":"Chong","year":"2007","journal-title":"ACS Chem. Biol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Xu, S., Wang, Y., Han, P., Yan, S., You, J., Guo, C., and Wu, X. (2024). Etamsylate-loaded hydrogel composed of carboxymethyl chitosan and oxidized tannic acid for improved wound healing. Int. J. Biol. Macromol., 279.","DOI":"10.1016\/j.ijbiomac.2024.135270"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1055\/s-0039-1693710","article-title":"Topically Applied Etamsylate: A New Orphan Drug for HHT-Derived Epistaxis (Antiangiogenesis through FGF Pathway Inhibition)","volume":"3","author":"Palacios","year":"2019","journal-title":"TH Open"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jama.1952.02930320016006","article-title":"Hormonal management of hereditary hemorrhagic talangiectasia","volume":"149","author":"Koch","year":"1952","journal-title":"J. Am. Med. Assoc."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/0140-6736(90)91010-8","article-title":"Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone","volume":"335","author":"Rutgeerts","year":"1990","journal-title":"Lancet"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.0954-6820.1981.tb11614.x","article-title":"Estrogen treatment of hereditary hemorrhagic telangiectasia. A double-blind controlled clinical trial","volume":"209","author":"Vase","year":"1981","journal-title":"Acta Med. Scand."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1288\/00005537-198203000-00017","article-title":"Use of estrogen in treatment of familial hemorrhagic telangiectasia","volume":"92","author":"Harrison","year":"1982","journal-title":"Laryngoscope"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/000348940211100306","article-title":"Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia","volume":"111","author":"Bergler","year":"2002","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0194-5998(03)00361-9","article-title":"Plasma surgery and topical estriol: Effects on the nasal mucosa and long-term results in patients with Osler\u2019s disease","volume":"129","author":"Sadick","year":"2003","journal-title":"Otolaryngol.-Head Neck Surg."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","article-title":"Estrogen receptor signaling mechanisms","volume":"116","author":"Fuentes","year":"2019","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood.V92.12.4677","article-title":"Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1","volume":"92","author":"Smith","year":"1998","journal-title":"Blood"},{"key":"ref_146","first-page":"525","article-title":"Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells","volume":"103","author":"Zarrabeitia","year":"2010","journal-title":"Thromb. Haemost."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/pediatric15010011","article-title":"Hereditary Hemorrhagic Telangiectasia in Pediatric Age: Focus on Genetics and Diagnosis","volume":"15","author":"Danesino","year":"2023","journal-title":"Pediatr. Rep."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"171","DOI":"10.7326\/0003-4819-109-2-171_1","article-title":"Hereditary hemorrhagic telangiectasia and danazol","volume":"109","author":"Haq","year":"1988","journal-title":"Ann. Intern. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-0037-1615709","article-title":"Hemostatic effects of tamoxifen in hereditary hemorrhagic telangiectasia","volume":"85","author":"Zacharski","year":"2001","journal-title":"Thromb. Haemost."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00005537-200404000-00021","article-title":"Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia","volume":"114","author":"Jameson","year":"2004","journal-title":"Laryngoscope"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1517\/14656566.2013.782002","article-title":"The use of raloxifene in osteoporosis treatment","volume":"14","author":"Isaia","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_152","unstructured":"European Medicines Agency, and Committee for Orphan Medicinal Products (2025, May 16). Raloxifene Hydrochloride for the Treatment of Hereditary Haemorrhagic Telangiectasia. 22 June 2010 EMA\/COMP\/90982\/2010. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu310730-public-summary-opinion-orphan-designation-raloxifene-hydrochloride-treatment-hereditary-haemorrhagic-telangiectasia_en.pdf."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/STROKEAHA.108.518621","article-title":"Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease","volume":"40","author":"Mosca","year":"2009","journal-title":"Stroke"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1160\/TH15-03-0239","article-title":"Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia","volume":"115","author":"Zarrabeitia","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Albi\u00f1ana, V., Cuesta, A.M., de Rojas-P, I., Gallardo-Vara, E., Recio-Poveda, L., Bernab\u00e9u, C., and Botella, L.M. (2020). Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061766"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"226","DOI":"10.7326\/0003-4819-144-3-200602070-00030","article-title":"Regression of cutaneous and gastrointestinal telangiectasia with sirolimus and aspirin in a patient with hereditary hemorrhagic telangiectasia","volume":"144","author":"Skaro","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1124\/mol.110.067447","article-title":"Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-\u03b21 signaling in endothelial cells","volume":"79","author":"Botella","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Hessels, J., Kroon, S., Boerman, S., Nelissen, R.C., Grutters, J.C., Snijder, R.J., Lebrin, F., Post, M.C., Mummery, C.L., and Mager, J.-J. (2022). Efficacy and Safety of Tacrolimus as Treatment for Bleeding Caused by Hereditary Hemorrhagic Telangiectasia: An Open-Label, Pilot Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11185280"},{"key":"ref_159","unstructured":"Faughnan, M.E., Bagheri, N., Vozoris, N.T., Sykes, J., Parlette, A., Chaparro, C., Oh, P., Marchuk, D.A., and Marambaud, P. Low-dose Tacrolimus for Epistaxis in Hereditary hemorrhagic Telangiectasia: Phase II Open Label Trial, Angiogenesis in press."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1172\/JCI127425","article-title":"Correcting Smad1\/5\/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models","volume":"130","author":"Ruiz","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/01.RES.0000159936.38601.22","article-title":"A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia","volume":"96","author":"Toporsian","year":"2005","journal-title":"Circ. Res."},{"key":"ref_162","first-page":"85","article-title":"The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: A pilot study","volume":"47","author":"Snijder","year":"2009","journal-title":"Rhinology"},{"key":"ref_163","first-page":"3826","article-title":"Integration of genotypic data into clinical trial design and reporting in hereditary hemorrhagic telangiectasia could help personalize treatment","volume":"109","author":"Modarresi","year":"2024","journal-title":"Haematologica"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/bloodadvances.2022007136","article-title":"Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation","volume":"6","author":"Joyce","year":"2022","journal-title":"Blood Adv."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ajhg.2024.12.002","article-title":"When \u201closs-of-function\u201d means proteostasis burden: Thinking again about coding DNA variants","volume":"112","author":"Shovlin","year":"2025","journal-title":"Am. J. Hum. Genet."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.stemcr.2022.05.022","article-title":"Vascular defects associated with hereditary hemorrhagic telangiectasia revealed in patient-derived isogenic iPSCs in 3D vessels on chip","volume":"17","author":"Orlova","year":"2022","journal-title":"Stem Cell Rep."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10456-023-09902-8","article-title":"Impact of heterozygous ALK1 mutations on the transcriptomic response to BMP9 and BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors","volume":"27","author":"Liu","year":"2024","journal-title":"Angiogenesis"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5603\/FHC.a2016.0022","article-title":"Doxycycline down-regulates matrix metalloproteinase expression and inhibits NF-\u03baB signaling in LPS-induced PC3 cells","volume":"54","author":"Ogut","year":"2016","journal-title":"Folia Histochem. Cytobiol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1096\/fj.03-0197fje","article-title":"Endoglin regulates nitric oxide-dependent vasodilatation","volume":"18","author":"Jerkic","year":"2004","journal-title":"FASEB J."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2012-06-435347","article-title":"Endothelial endoglin is involved in inflammation: Role in leukocyte adhesion and transmigration","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s00018-015-2099-4","article-title":"Endoglin regulates mural cell adhesion in the circulatory system","volume":"73","author":"Rossi","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00018-017-2694-7","article-title":"Human endoglin as a potential new partner involved in platelet-endothelium interactions","volume":"75","author":"Rossi","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Egido-Turri\u00f3n, C., Rossi, E., Ollauri-Ib\u00e1\u00f1ez, C., P\u00e9rez-Garc\u00eda, M.L., Sevilla, M.A., Bastida, J.M., Gonz\u00e1lez-Porras, J.R., Rodr\u00edguez-Barbero, A., Bernabeu, C., and Lopez-Novoa, J.M. (2022). Functional Alterations Involved in Increased Bleeding in Hereditary Hemorrhagic Telangiectasia Mouse Models. Front. Med., 9.","DOI":"10.3389\/fmed.2022.871903"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood.2023021765","article-title":"How I treat bleeding in hereditary hemorrhagic telangiectasia","volume":"144","year":"2024","journal-title":"Blood"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e176379","DOI":"10.1172\/JCI176379","article-title":"Hereditary hemorrhagic telangiectasia: From signaling insights to therapeutic advances","volume":"134","author":"Tourvieilhe","year":"2024","journal-title":"J. Clin. Investig."}],"updated-by":[{"DOI":"10.3390\/jcm15062153","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000}}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7724\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:15:15Z","timestamp":1773321315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":175,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14217724"],"URL":"https:\/\/doi.org\/10.3390\/jcm14217724","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}